Literature DB >> 24438645

Gallbladder carcinoma: a New Zealand centre's 10-year experience with presentation, ethnic diversity and survival rate.

Nikola Lilic1, Ben Addison, Hisham Hammodat.   

Abstract

BACKGROUND: Gallbladder cancer is a high-mortality cancer with a wide range of incidence worldwide. Some indigenous populations are known to have a higher incidence of gallbladder cancer. Commonly, it is incidentally discovered during routine gallbladder surgery. The primary aim was to determine the incidence and characteristics of gallbladder cancer in a New Zealand population. The secondary aim was to determine if inequalities in gallbladder cancer rates between Māori and non-Māori have decreased.
METHODS: A retrospective cohort study utilizing an online database was conducted to identify all patients with gallbladder malignancy treated in the Waitemata District Health Board from 2003 to 2013. The outcomes measured were staging of cancer, histology, ethnicity, incidental finding and survival rates.
RESULTS: The age-standardized incidence (ASI) rate of gallbladder carcinoma is 0.60/100 000. The gender-specific ASI rates were 0.21/100 000 (men) and 0.76/100 000 (women). The incidence for Māori was 0.96/100 000 (men) and 1.37/100 000 (women). Gallbladder carcinoma was found incidentally in 0.44% of cholecystectomies, which made up 46.2% of all cases. Right upper quadrant pain was the most common presenting symptom (74.4%). Surgery was the most common treatment modality (66.7%). Mean survival across all patients was 12.24 months.
CONCLUSION: Our study found that the ASI of gallbladder carcinoma when compared with the Koea et al. study has decreased for men from New Zealand, but appears to have increased slightly for women from New Zealand. The raw incidence for Māori men and women appears to have decreased, but inequality in gallbladder cancer incidence between Māori and non-Māori remains.
© 2014 Royal Australasian College of Surgeons.

Entities:  

Keywords:  carcinoma; epidemiology; gall bladder; gallstone

Mesh:

Year:  2014        PMID: 24438645     DOI: 10.1111/ans.12503

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  6 in total

1.  High-Quality Surgery for Gallbladder Carcinoma: Rare, Associated with Disparity, and Not Substitutable by Chemotherapy.

Authors:  Omid Salehi; Eduardo A Vega; Sebastian Mellado; Michael J Core; Mu Li; Olga Kozyreva; Onur C Kutlu; Richard Freeman; Claudius Conrad
Journal:  J Gastrointest Surg       Date:  2022-04-08       Impact factor: 3.267

2.  Upregulation of long non-coding RNA HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition in gallbladder carcinoma.

Authors:  Peng Zhang; Peihua Cao; Xiaofeng Zhu; Mingxin Pan; Kebo Zhong; Rui He; Yang Li; Xingyuan Jiao; Yi Gao
Journal:  Oncotarget       Date:  2017-05-16

3.  Long non-coding RNA CRNDE promotes gallbladder carcinoma carcinogenesis and as a scaffold of DMBT1 and C-IAP1 complexes to activating PI3K-AKT pathway.

Authors:  Sheng Shen; Han Liu; Yueqi Wang; Jiwen Wang; Xiaolin Ni; Zhilong Ai; Hongtao Pan; Houbao Liu; Yebo Shao
Journal:  Oncotarget       Date:  2016-11-08

Review 4.  Safe, selective histopathological examination of gallbladder specimens: a systematic review.

Authors:  V P Bastiaenen; J E Tuijp; S van Dieren; M G Besselink; T M van Gulik; L Koens; P J Tanis; W A Bemelman
Journal:  Br J Surg       Date:  2020-07-08       Impact factor: 6.939

5.  Ethnic Differences in Cancer Rates Among Adults With Type 2 Diabetes in New Zealand From 1994 to 2018.

Authors:  Dahai Yu; Zheng Wang; Yamei Cai; Kate McBride; Uchechukwu Levi Osuagwu; Karen Pickering; John Baker; Richard Cutfield; Brandon J Orr-Walker; Gerhard Sundborn; Michael B Jameson; Zhanzheng Zhao; David Simmons
Journal:  JAMA Netw Open       Date:  2022-02-01

6.  Gallbladder cancer in Eastern Province of Saudi Arabia: A retrospective cohort study.

Authors:  Mohammed Yousef Aldossary; Amal Ali Alayed; Samir S Amr; Shareef Alqahtani; Mamdouh Alnahawi; Mohammed Saad Alqahtani
Journal:  Ann Med Surg (Lond)       Date:  2018-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.